All In Biotech

Drug Trial Radar · NCT05654623

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 624 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

624

Actual

Start

Mar 3, 2023

Primary completion

Jan 31, 2025

Study completion May 15, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Arvinas Estrogen Receptor, Inc.
First posted
Dec 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Conditions

  • Advanced Breast Cancer

Interventions

  • ARV-471Drug

    orally, once daily on a 28-day continuous dosing schedule

  • FulvestrantDrug

    intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized ParticipantsTime frame: From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
  2. PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 MutationTime frame: From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)

Locations

312 sites in 31 countries. Site status is shown where the registry gives one.

  • California Cancer Associates for Research and Excellence, Inc. (cCARE)

    Encinitas, California

  • Orange Coast Memorial Medical Center

    Fountain Valley, California

  • California Cancer Associates for Research and Excellence

    Fresno, California

  • Providence Queen of the Valley Medical Center

    Napa, California

  • California Cancer Associates for Research and Excellence

    San Marcos, California

  • Olive View-UCLA Medical Center

    Sylmar, California

  • Smilow Cancer Hospital Care Center at Fairfield

    Fairfield, Connecticut

  • Smilow Cancer Hospital at Yale-New Haven

    New Haven, Connecticut

  • Yale-New Haven Hospital

    New Haven, Connecticut

  • Smilow Cancer Hospital/Phase 1 Clinic

    New Haven, Connecticut

  • Smilow Cancer Hospital Care Center at North Haven

    North Haven, Connecticut

  • Smilow Cancer Hospital Care Center at Trumbull

    Trumbull, Connecticut

  • Florida Cancer Specialists BON

    Bonita Springs, Florida

  • Florida Cancer Specialists LRS

    Bradenton, Florida

  • Florida Cancer Specialists NFM

    Cape Coral, Florida

  • Morton Plant Hospital - BayCare Health System

    Clearwater, Florida

  • Florida Cancer Specialists

    Clearwater, Florida

  • Florida Cancer Specialists

    Daytona Beach, Florida

  • Florida Cancer Specialist

    Fleming Island, Florida

  • Florida Cancer Specialists - South

    Fort Myers, Florida

  • Florida Cancer Specialists COL

    Fort Myers, Florida

  • Florida Cancer Specialists GLO

    Fort Myers, Florida

  • Florida Cancer Specialists

    Gainesville, Florida

  • Lakeland Regional Cancer Center

    Lakeland, Florida

  • Florida Cancer Specialists

    Largo, Florida

  • Florida Cancer Specialists

    Lecanto, Florida

  • Florida Cancer Specialist And Research Institute

    N. Venice, Florida

  • Florida Cancer Specialists NGD

    Naples, Florida

  • Florida Cnacer Specialists

    North Port, Florida

  • Florida Cancer Specialists

    Ocala, Florida

  • Florida Cancer Specialists

    Orlando, Florida

  • Florida Cancer Specialists PCH

    Port Charlotte, Florida

  • Florida Cancer Specialists SAD

    Sarasota, Florida

  • Florida Cancer Specialists

    St. Petersburg, Florida

  • Florida Cancer Specialists

    Tampa, Florida

  • Florida Cancer Specialists

    The Villages, Florida

  • Florida Cancer Specialist

    Trinity, Florida

  • Florida Cancer Specialists

    Wellington, Florida

  • Florida Cancer Specialists

    West Palm Beach, Florida

  • Florida Cancer Specialists

    Winter Park, Florida

Showing 40 of 312 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.